Members are advised of changes and updates to the Pharmaceutical Benefits Scheme. Several changes to the Pharmaceutical ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.

SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

4Q23 results included charges related to the Daiichi Sankyo collaboration .

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...